

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\050\2024-25

Date: 11.10.2024

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
“Exchange Plaza”, Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Subject: Completion of Business Transfer Agreement with Thyrocare Technologies Limited

Reference: Our letter dated 30th August 2024- Intimation regarding Company’s execution of Business Transfer Agreement (“BTA”) with Thyrocare Technologies Limited

This is further to our letter dated 30th August, 2024, wherein we had intimated to the Stock Exchanges regarding execution of Business Transfer Agreement (“BTA”) with Thyrocare Technologies Limited (“Thyrocare”) for transferring and selling our diagnostic and pathological services business as a going concern (on a slump sale basis), which was subject to fulfilment of the Conditions Precedent (“CP”) as set out in the BTA.

We would like to inform you that, the Company has completed the sale and transferred its Diagnostic and pathological services business as a going concern on 11th October 2024, at 12.30 PM in terms of the said BTA and ceased the relevant operations w.e.f. 11th October 2024.

This is for your information and records.

Thanking you,

Yours faithfully,
For Vimta Labs Limited

Sujani Vasireddi
Company Secretary



Page 1 of 1